Intellia Therapeutics Inc

NASDAQ:NTLAUnited States

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Contact Information

Headquarters

40 Erie St Ste 130CAMBRIDGE, MA, United States 02139-4254

Phone

857-285-6200

Fax

302-655-5049

Executives

Independent Chairman of the Board

Frank Verwiel

President, Chief Executive Officer, Director

John Leonard

Chief Financial Officer, Executive Vice President, Treasurer

Glenn Goddard

Executive Vice President, Chief Technology Officer

Eliana Clark

Executive Vice President, Chief Scientific Officer

Laura Sepp-Lorenzino